AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 243 min read$ABBV

AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales

AbbVie (ABBV) received FDA approval for at-home Skyrizi starts in Crohn's disease, potentially boosting sales. The approval allows patients to begin treatment at home with an on-body injector. Shares closed at $285.64 on October 23. Third-quarter results are due on October 30, with revenue guidance around $17.2 billion. Analysts expect a potential total return of ~27% with a target price of ~$364.

Original reporting
finance.yahoo.com
Published Oct 24, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

The new label could expand the drug's addressable market and improve patient convenience, potentially boosting sales once insurers grant coverage.

02

Market read

First‑report FDA approval for a major Crohn's therapy; likely to influence AbbVie's upcoming earnings guidance and peer dynamics.

03

What to watch

Competition from JNJ's Tremfya and potential pricing pressures could temper the impact.

Relevance 7/10Novelty 9/10Timing: post‑approval, impact will unfold before the Q3 earnings call on Oct 30

Background

AbbVie announced FDA clearance for a subcutaneous induction regimen of Skyrizi, allowing patients to start treatment at home, a shift from the prior IV‑only approach.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

FDA approved at‑home Skyrizi induction for Crohn's, a new indication that could drive future sales once formulary access is secured.

Expected impact

likely pressure to the upside as investors price in future sales, though timing depends on payer adoption.

Evidence & confidence

The approval is a primary disclosure for a large‑cap biotech; market typically reacts positively to new administration routes that broaden patient access.

Market effects

Sector

Strengthens the broader IBD/auto‑immune therapeutic sector and may pressure peers like JNJ.

Regional

U.S. biotech market sees incremental boost; no immediate global ripple.

Global

Limited to U.S. investors; the approval does not affect broader macro factors.

Counterpoint

What could challenge this read

If payer formulary delays persist, the approval may not translate into near‑term revenue, limiting upside.

Key entities

  • Company
    AbbVie

    Pharmaceutical firm receiving FDA approval for at‑home Skyrizi.

  • Company
    Johnson & Johnson

    Competitor with Tremfya, mentioned for context.

Read at source← All news

StoryFDA approves at‑home subcutaneous induction regimen for AbbVie’s SKYRIZI in Crohn’s disease

Also covered by

6 outlets

Related articles

OCT 23
$ABBVHigh

Abbvie Announces U.S. Fda Approval of Subcutaneous Induction Regimen for Skyrizi for Adults with Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval follows positive Phase 3 trial results, showing significant clinical remission and endoscopic response in patients. SKYRIZI can now be administered at home using an on-body injector, with induction doses at weeks 0, 2, 4, and 8, followed by maintenance dosing every eight weeks.

marketscreener.com2 min
OCT 23
$ABBVHigh

AbbVie (ABBV) Gains FDA Nod for At-Home Skyrizi Induction in Cro

AbbVie (ABBV) received FDA approval for an at-home subcutaneous induction regimen for its drug Skyrizi, allowing adults with moderate to severe Crohn’s disease to start treatment at home. The company offers a 2.34% dividend yield with a high payout ratio of 85% and a 3-year dividend growth rate of 5.2%. AbbVie's GF Value™ suggests the stock is modestly overvalued at $222.72 versus the current price of $286.20.

gurufocus.com3 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SK

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on positive Phase 3 AFFIRM trial results, showing superior clinical remission and endoscopic response at week 12 compared to placebo, especially in treatment-naïve patients. The subcutaneous form allows for at-home administration using an on-body injector.

gurufocus.com2 min
OCT 23
$ABBVHigh

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi

AbbVie (ABBV) received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn's disease. The regimen involves 720 mg doses at weeks 0, 2, 4, and 8, with maintenance doses every 8 weeks. The approval is based on Phase 3 trial results showing 56% clinical remission vs. 30% for placebo. The FDA also updated prescribing info to remove mandatory TB testing. Skyrizi is approved for several autoimmune diseases.

investing.com2 min